Subarachnoid Hemorrhage, AneurysmalPhase 3TALISCHER-SAHNCT07821008
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
A Phase 3 study testing Experimental group: ticagrelor in people with Subarachnoid Hemorrhage, Aneurysmal and Brain Ischemia, run by University Hospital, Toulouse at 7 sites in France.
Trial summary
Among aneurysmal subarachnoid hemorrhage (aSAH) survivors, ischemic injuries such as peri procedural thromboembolic events (TEE) and delayed cerebral ischemia (DCI) represent the most important disabling complications. However, preventive strategies are limited. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia, Endovascular Procedure
- What is being tested?
- Experimental group: ticagrelor
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 274 participants
- Where
- 7 sitesFrance
- Study dates
- 24 Nov 2026to 14 Dec 2029
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 - 80 years old
- Low grade aneurysmal subarachnoid hemorrhage defined by a WFNS 1-3
- Aneurysmal treatment planned to be completed within 72 h after rupture
- Sacciform aneurysm diameter ≥ 4 mm
- Ruptured aneurysm treatable by endovascular, endo-saccular technic (stent and flow diverters are not allowed). If the aneurysm responsible of the SAH is difficult to identify, several aneurysms that may be related to the SAH can be treated during the procedure.
- Affiliated person or beneficiary of a social security scheme.
- Free, informed and written consent signed by the participant or truthworthy/proxy representative and the investigator (at the latest on the day of inclusion and before any examination required by the research).
Who cannot join
- Poor grade aSAH defined as WFNS 4 and 5
- Fusiform, dissecting, thrombosed aneurysms and aneurysm associated with brain arteriovenous malformation
- Associated unruptured aneurysm requiring treatment within 3 months
- History of intracranial hemorrhage within the past 6 months
- Intraparenchymal hematoma associated with SAH -Ongoing antiplatelet drug
- Acute symptomatic hydrocephalus or ventricular derivation
Show all 15Show fewer
- Intra-ventricular hemorrhage on admission CT scan, filling >50% of both lateral ventricles and 3rd and 4th ventricles
- Pre aSAH mRS ≥
- Active pathological bleeding and notably recent extra cranial hemorrhage (within previous 30 days), gastrointestinal hemorrhage within the past 6 months, or major surgery within 30 days
- Other contra-indications to Ticagrelor: hypersensitivity to the active substance or to any of the excipients,
- Severe hepatic or kidney failure,
- Concomitant administration of strong CYP3A4 inhibitors(for ex ketoconazole, clarithromycine, nefazodone, ritonavir and atazanavir) drugs that interfered with P-glycoprotein transporter
- Respiratory failure, asthma , obstructive broncho-pneumopathy
- Pregnant and breastfeeding women
- Patients under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision
Trial locations and contacts
7 sites in 1 country. Contact the study team or a site near you to ask about taking part.
7 sites in 1 country
France7 sites
GH Pellegrin
Bordeaux, 33 000
Gaultier Marnat, MD, 05 57 82 17 65 ext. +33, gaultier.marnat@chu-bordeaux.fr
Gaultier Marnat, MD
Gui de Chauliac Hospital - Montpellier University Hospital
Montpellier, 34 295
Kevin Chalard, MD, 04 67 33 76 87 ext. +33, k-chalard@chu-montpellier.fr
Kevin Chalard, MD
Nord Laennec Hospital - Nantes University Hospital
Nantes, 44 800
Jean-Marc Le Goff, MD, 02 40 16 53 04 ext. +33, jeanmarc.legoff@chu-nantes.fr
Jean-Marc Le Goff, MD
Fondation Adolphe de Rothschild Hospital
Paris, 75 019
Arthur Gutter, MD, 01 48 03 68 31 ext. +33, agutter@for.paris
Arthur Gutter, MD
Hautepierre Hospital - Strasbourg Hospital University
Strasbourg, 67 200
Raoul Pop, MD, 03 88 12 78 71 ext. +33, raoul.pop@chru-strasbourg.fr
Raoul Pop, MD
Pierre Paul Riquet Hospital - Toulouse University Hospital
Toulouse, 31 300
Lionel Calvière, MD, 05 61 77 94 86 ext. +33, calviere.l@chu-toulouse.fr
Lionel Calvière, MD
Bretonneau Hospital - Tours Regional University Hospital
Tours, 37 000
Heloise Ifergan, MD, 06 61 61 67 51 ext. +33, h.ifergan@chu-tours.fr
Heloise Ifergan, MD
About this study
Among aneurysmal subarachnoid hemorrhage (aSAH) survivors, ischemic injuries such as peri procedural thromboembolic events (TEE) and delayed cerebral ischemia (DCI) represent the most important disabling complications. However, preventive strategies are limited. Platelet activation mechanisms play a critical role in the pathophysiology of TEE and DCI. The results of several meta analyses suggested that use of antiplatelet drugs (APD) could reduce the risk of TTE/DCI. We aim to evaluate in patients with a low grade aSAH (WFNS 1 to 3) that occurred for less than 72 hours ago, the effect of 14 days course of ticagrelor vs placebo, initiated at the beginning of the endovascular treatment of the aneurysm, on the ischemic complications (peri-procedural symptomatic and asymptomatic TEE and/or neurological worsening due to DCI) occurring within 14 days of the endovascular treatment of the aneurysm.
Read the detailed description
After aSAH, ischemic complications such as peri-procedural TEE and DCI prevalence are as high as 15 and 30% of the patients respectively. They are the main causes of disability in patients who survive the initial bleeding. The diagnoses of TEE and DCI may be difficult in patients experiencing high grade aSAH contrariwise to low grade where clinical exam and reliable imaging of brain ischemia could be performed. In addition, TEE/DCI dramatically impact the prognosis of these patients who had no/minor initial deficit. Platelet activation and thrombo-inflammatory mechanisms play a critical role in the pathophysiology of TEE and DCI through multiple pathways. Several APD have been evaluated to mitigate TEE/DCI risk with heterogeneous results. A recent metanalysis suggested that APD could reduce TEE incidence by 13 %. Interestingly patients receiving mono or dual APD just before aneurysmal repair did not experience an increased hemorrhagic risk. Regarding DCI, aspirin failed to demonstrate any benefit in an European randomized controlled trial while 3 recent meta-analyses suggested that APD use may be associated with a relative risk reduction of 40-50%. Hence, in the absence of positive trials no APD use is not recommended for the management of aSAH. Compared to previous APD used in aSAH, Ticagrelor, a reversible P2Y12 receptor inhibitor, has a promising profile to control TEE/ DCI: stronger and shorter antiplatelet action as well as vasodilatory and anti-inflammatory effects.
Two hundred and seventy-four patients will be randomized 1:1 in Ticagrelor or placebo group within 72hrs of aneurysm rupture in a multicentre prospective double-blind, parallel group study. Ticagrelor/placebo will be administered orally just before the endovascular treatment of the aneurysm with a loading dose of 180 mg, followed by 90 mg twice a day during 2 weeks. We will assess a composite primary end point based on the occurrence of ischemic complications: peri-procedural asymptomatic and symptomatic TEE and/or neurological deterioration due to DCI. During the first 24H, TEE is defined by clotting or arterial occlusion on angiography during endovascular procedure and/or 24hrs-MRI infarctions and/or neurological deterioration defined by the worsening ≥2pts from baseline on NIHSS performed immediately after the intervention, then every 6 hours. From day 2 to 15, multi daily clinical monitoring using NIHSS will be performed to assess the occurrence of neurological deterioration due to DCI, defined as worsening ≥2pts on NIHSS, lasting for at least 2hrs. A brain imaging- MRI recommended- is needed in the case of neurological deterioration to confirm its ischemic mechanism. Rescue therapies for DCI will be feasible according to a decisional algorithm. Systematic MRI will be performed within the 24hrs of the endovascular procedure and 15 days after randomization in order to detect, confirm and quantify cerebral infarcts. At 3 months, visit will include functional outcome with the mRS and the GOSE, cognitive functions with the Montreal Cognitive Assessment (MoCA) and quality of life using EQ-5D. Any hemorrhagic complication related to SAH (rebleeding during the procedure, hydrocephalus requiring ventricular drain, intracerebral hemorrhage) other major bleedings and side effects of the treatment such as dyspnea will be carefully monitored and reported.
- Being tested
- Experimental group: ticagrelor, Control group: placebo
- Keywords
- Aneurysmal subarachnoid hemorrhage, platelet aggregation inhibitors, ticagrelor, thromboembolic events, delayed cerebral ischemia
- Medical subject headings
- Subarachnoid Hemorrhage, Brain Ischemia, Thromboembolism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Experimental group: ticagrelorDrug
Patients with a low grade aSAH receiving ticagrelor. Ticagrelor will be administered orally just before the endovascular treatment of the ruptured aneurysm with a loading dose of 180mg, followed by 90 mg twice a day during 2 weeks.
Control group: placeboDrug
Patients with a low grade aSAH receiving placebo. Placebo will consist of tablets identical to ticagrelor ones, administered orally with a loading dose of 2 tablets, followed by 1 tablet twice a day during 2 weeks
| Study group | Role | What they receive |
|---|---|---|
| Ticagrelor | Experimental | Not described Receives: Drug: Experimental group: ticagrelor |
| Placebo | Placebo comparator | Not described Receives: Drug: Control group: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Effect of tricagrelor on the ischemic complications: peri-procedural thromboembolic events
It will be assessed by the occurence of symptomatic and asymptomatic peri-procedural thromboembolic events within the first 24 hours after the procedure.
These events can be :
- angiographic : any event with clotting near the neck of the aneurysm or in distal branches and parent vessel occlusion in any vascular territory during procedure, and/or
- Clinical: worsening neurological deficit ≥2 points on NHISS from baseline after the procedure not attribuable to other causes, and/or
- Imaging: acute infarctus on 24h MRI The NIHSS (National Institutes of Health Stroke Scale) is a clinical scale used primarily to assess the severity of a stroke. It consists of 15 items which assigns a score ranging from 0 to 42 (0 corresponds to no measurable deficit and 42 to the maximum neurological deficit).
Measured: 24 hours
Effect of tricagrelor on the ischemic complications: neurological deterioration
It will be assessed by the occurence of neurological deterioration due to delayed cerebral ischemia DCI within 14 days of the endovascular treatment.
It will be caracterized by a worsening deficit (≥2 points on NIHSS scale from the previous evaluation), lasting at least 2 hours, not attributed to other causes.
Measured: 14 days
Secondary outcomes (17)
Peri-procedural asymptomatic and symptomatic TEE: angiographic
It will be assessed by the occurence of one peri-procedural angiographic TEE that is, any event with clotting near the neck of the aneurysm or in distal branches and parent vessel occlusion in any vascular territory during procedure within 24 hours of aneurysmal treatment.
Measured: 24 hours
Peri-procedural asymptomatic and symptomatic TEE: clinical
It will be assessed by the occurence of at least one peri-procedural clinical TEE that is, symptomatic ischemic lesions defined by a worsening ≥2pts on NIHSS from baseline, not attributable to other causes within 24 hours of aneurysmal treatment.
Measured: 24 hours
Peri-procedural asymptomatic and symptomatic TEE: ischemic lesion
It will be assessed by the occurence of at least one severe symptomatic ischemic lesion defined by worsening >4 points on NIHSS from baseline within 24 hours after the aneurysmal treatment.
Measured: 24 hours
Peri-procedural asymptomatic and symptomatic TEE: imaging
It will be assessed by the occurence of at least one peri-procedural TEE that is, acute infarctus on MRI performed within 24 hours after endovascular treatment.
Measured: 24 hours
Neurological deterioration and asymptomatic lesions on MRI due to DCI
It will be assessed by the occurence of at least one neurological deterioration due to DCI (worsening ≥2pts on NIHSS compared with previous evaluation), lasting at least 2 hrs, not attributed to other causes after a brain imaging at day 15.
Measured: 15 days
Neurological deterioration and asymptomatic lesions on MRI due to DCI: severe neurological deterioration
It will be assessed by the occurence of at least one severe neurological deterioration due to DCI defined by worsening >4 points on NIHSS compared to previous evaluation, at day 15.
Measured: 15 days
Neurological deterioration and asymptomatic lesions on MRI due to DCI: asymptomatic MRI lesions
It will be assessed by the occurence of new infarctus on MRI at day 15.
Measured: 15 days
Neurological deterioration and asymptomatic lesions on MRI due to DCI: ischemic event
It will be assessed by the occurence of at least one ischemic event (clinical/MRI) related to DCI, at day 15.
Measured: 15 days
Total incidence of ischemic events per patient
It will be assessed by the combined incidence of all ischemic events: sum of both type of ischemic events (related to TEE and/or DCI) at day 15.
Measured: 15 days
Need for rescue therapy during embolization and/or DCI
It will be assessed by the rate of rescue therapy for angiography defined by any mechanical maneuvers (catheter aspiration, stentrievers use or any pharmacological intra-arterial or intravenous therapies) within 14 days of treatment.
Measured: 14 days
Aneurysm occlusion
It will be assessed by the quality of the aneurysm occlusion evaluated at procedure completion, 24 hours and 3 months MRI/MRA based on the Raymond-Roy classification.
The Raymond-Roy classification is an angiographic classification used to describe the degree of aneurysm occlusion:
- Class 1: complete occlusion
- Class 2: residual neck
- Class 3: residual aneurysm.
Measured: 3 months
Clinical outcome at 3 months: good functionnal outcome (disability and functional dependence)
It will be assessed by the Modified Rankin Scale (mRS) with a score that must be below 3. It is a clinical scale that measures a patient's degree of disability and functional dependence on a scale from 0 to 6 (the higher the score, the greater the disability and dependence).
It will be performed at visit 16 (3 months).
Measured: 3 months
Clinical outcome at 3 months: good functional outcome (disability and recovery)
It will be assessed by the GOSE (Glasgow Outcome Scale-Extended) with a score that must be above 5. It is a scale used to assess the level of recovery and disability following a brain injury; it has 8 levels, ranging from 1 (death) to 8 (good recovery).
It will be performed at visit 16 (3 months).
Measured: 3 months
Clinical outcome at 3 months: quality of life
It will be assessed by the EQ-5D questionnaire at visit 16 (3 months). It is a health-related quality of life questionnaire that assesses five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item is rated on a 5-point scale, resulting in a total score ranging from 1 to 100, where 0 represents the worst possible health status and 100 represents the best.
Measured: 3 months
Clinical outcome at 3 months: cognitive deterioration
The rate of cognitive deterioration will be defined by a MoCA score below or equal to 25, performed at visit 16 (3 months).
The MoCA (Montreal Cognitive Assessment) is a screening test for cognitive disorders that yields a score ranging from 0 to 30 (where 0 indicates severely impaired cognitive function and 30 indicates optimal performance).
Measured: 3 months
Clinical outcome at 3 months: deaths
It will be assessed by the number of deaths occuring during the totality of the research (3 months).
Measured: 3 months
Occurence of adverse events
All adverse events during the totality of the research (3 months) will be collected.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2026
- Study start24 Nov 2026 (estimated)
- Primary completion14 Dec 2029 (estimated)
- Study completion14 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Subarachnoid Hemorrhage, AneurysmalStudies of the same condition, open and under way.
- More trials run by University Hospital, ToulouseThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 274 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Toulouse
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Lionel Calvière, Principal investigator, Toulouse Hospital University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07821008
- Sponsor's protocol ID
- RC31/23/0369
- Other IDs
- 2023-509795-42-00, 2023
- Acronym
- TALISCHER-SAH
- Status last verified
- Nov 2026
- First submitted
- 24 Aug 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
- ClinicalTrials.gov ID
- NCT07821008
- Acronym / sponsor ID
- TALISCHER-SAH / RC31/23/0369
- Keywords
- Aneurysmal subarachnoid hemorrhage, platelet aggregation inhibitors, ticagrelor, thromboembolic events, delayed cerebral ischemia
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 274 participants (estimated)
- Lead sponsor
- University Hospital, ToulouseUniversity, hospital or other
- Study start
- 24 Nov 2026 (estimated)
- Primary completion
- 14 Dec 2029 (estimated)
- Study completion
- 14 Dec 2029 (estimated)
- First posted
- 15 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Among aneurysmal subarachnoid hemorrhage (aSAH) survivors, ischemic injuries such as peri procedural thromboembolic events (TEE) and delayed cerebral ischemia (DCI) represent the most important disabling complications. However, preventive strategies are limited. Platelet activation mechanisms play a critical role in the pathophysiology of TEE and DCI. The results of several meta analyses suggested that use of antiplatelet drugs (APD) could reduce the risk of TTE/DCI. We aim to evaluate in patients with a low grade aSAH (WFNS 1 to 3) that occurred for less than 72 hours ago, the effect of 14 days course of ticagrelor vs placebo, initiated at the beginning of the endovascular treatment of the aneurysm, on the ischemic complications (peri-procedural symptomatic and asymptomatic TEE and/or neurological worsening due to DCI) occurring within 14 days of the endovascular treatment of the aneurysm.
Detailed description
After aSAH, ischemic complications such as peri-procedural TEE and DCI prevalence are as high as 15 and 30% of the patients respectively. They are the main causes of disability in patients who survive the initial bleeding. The diagnoses of TEE and DCI may be difficult in patients experiencing high grade aSAH contrariwise to low grade where clinical exam and reliable imaging of brain ischemia could be performed. In addition, TEE/DCI dramatically impact the prognosis of these patients who had no/minor initial deficit. Platelet activation and thrombo-inflammatory mechanisms play a critical role in the pathophysiology of TEE and DCI through multiple pathways. Several APD have been evaluated to mitigate TEE/DCI risk with heterogeneous results. A recent metanalysis suggested that APD could reduce TEE incidence by 13 %. Interestingly patients receiving mono or dual APD just before aneurysmal repair did not experience an increased hemorrhagic risk. Regarding DCI, aspirin failed to demonstrate any benefit in an European randomized controlled trial while 3 recent meta-analyses suggested that APD use may be associated with a relative risk reduction of 40-50%. Hence, in the absence of positive trials no APD use is not recommended for the management of aSAH. Compared to previous APD used in aSAH, Ticagrelor, a reversible P2Y12 receptor inhibitor, has a promising profile to control TEE/ DCI: stronger and shorter antiplatelet action as well as vasodilatory and anti-inflammatory effects.
Two hundred and seventy-four patients will be randomized 1:1 in Ticagrelor or placebo group within 72hrs of aneurysm rupture in a multicentre prospective double-blind, parallel group study. Ticagrelor/placebo will be administered orally just before the endovascular treatment of the aneurysm with a loading dose of 180 mg, followed by 90 mg twice a day during 2 weeks. We will assess a composite primary end point based on the occurrence of ischemic complications: peri-procedural asymptomatic and symptomatic TEE and/or neurological deterioration due to DCI. During the first 24H, TEE is defined by clotting or arterial occlusion on angiography during endovascular procedure and/or 24hrs-MRI infarctions and/or neurological deterioration defined by the worsening ≥2pts from baseline on NIHSS performed immediately after the intervention, then every 6 hours. From day 2 to 15, multi daily clinical monitoring using NIHSS will be performed to assess the occurrence of neurological deterioration due to DCI, defined as worsening ≥2pts on NIHSS, lasting for at least 2hrs. A brain imaging- MRI recommended- is needed in the case of neurological deterioration to confirm its ischemic mechanism. Rescue therapies for DCI will be feasible according to a decisional algorithm. Systematic MRI will be performed within the 24hrs of the endovascular procedure and 15 days after randomization in order to detect, confirm and quantify cerebral infarcts. At 3 months, visit will include functional outcome with the mRS and the GOSE, cognitive functions with the Montreal Cognitive Assessment (MoCA) and quality of life using EQ-5D. Any hemorrhagic complication related to SAH (rebleeding during the procedure, hydrocephalus requiring ventricular drain, intracerebral hemorrhage) other major bleedings and side effects of the treatment such as dyspnea will be carefully monitored and reported.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Ticagrelor | Experimental | Drug: Experimental group: ticagrelor |
| Placebo | Placebo comparator | Drug: Control group: placebo |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age 18 - 80 years old
- Low grade aneurysmal subarachnoid hemorrhage defined by a WFNS 1-3
- Aneurysmal treatment planned to be completed within 72 h after rupture
- Sacciform aneurysm diameter ≥ 4 mm
- Ruptured aneurysm treatable by endovascular, endo-saccular technic (stent and flow diverters are not allowed). If the aneurysm responsible of the SAH is difficult to identify, several aneurysms that may be related to the SAH can be treated during the procedure.
Key exclusion criteria (15 listed)
- Poor grade aSAH defined as WFNS 4 and 5
- Fusiform, dissecting, thrombosed aneurysms and aneurysm associated with brain arteriovenous malformation
- Associated unruptured aneurysm requiring treatment within 3 months
- History of intracranial hemorrhage within the past 6 months
- Intraparenchymal hematoma associated with SAH -Ongoing antiplatelet drug
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Experimental group: ticagrelorPatients with a low grade aSAH receiving ticagrelor. Ticagrelor will be administered orally just before the endovascular treatment of the ruptured aneurysm with a loading dose of 180mg, followed by 90 mg twice a day during 2 weeks. | Drug | Ticagrelor |
| Control group: placeboPatients with a low grade aSAH receiving placebo. Placebo will consist of tablets identical to ticagrelor ones, administered orally with a loading dose of 2 tablets, followed by 1 tablet twice a day during 2 weeks | Drug | Placebo |
Primary outcome
Effect of tricagrelor on the ischemic complications: peri-procedural thromboembolic events
Time frame: 24 hours
It will be assessed by the occurence of symptomatic and asymptomatic peri-procedural thromboembolic events within the first 24 hours after the procedure. These events can be : * angiographic : any event with clotting near the neck of the aneurysm or in distal branches and parent vessel occlusion in any vascular territory during procedure, and/or * Clinical: worsening neurological deficit ≥2 points on NHISS from baseline after the procedure not attribuable to other causes, and/or * Imaging: acute infarctus on 24h MRI The NIHSS (National Institutes of Health Stroke Scale) is a clinical scale used primarily to assess the severity of a stroke. It consists of 15 items which assigns a score ranging from 0 to 42 (0 corresponds to no measurable deficit and 42 to the maximum neurological deficit).
Effect of tricagrelor on the ischemic complications: neurological deterioration
Time frame: 14 days
It will be assessed by the occurence of neurological deterioration due to delayed cerebral ischemia DCI within 14 days of the endovascular treatment. It will be caracterized by a worsening deficit (≥2 points on NIHSS scale from the previous evaluation), lasting at least 2 hours, not attributed to other causes.
17 secondary outcomes
Peri-procedural asymptomatic and symptomatic TEE: angiographic
Time frame: 24 hours
Peri-procedural asymptomatic and symptomatic TEE: clinical
Time frame: 24 hours
Peri-procedural asymptomatic and symptomatic TEE: ischemic lesion
Time frame: 24 hours
Peri-procedural asymptomatic and symptomatic TEE: imaging
Time frame: 24 hours
Neurological deterioration and asymptomatic lesions on MRI due to DCI
Time frame: 15 days
Neurological deterioration and asymptomatic lesions on MRI due to DCI: severe neurological deterioration
Time frame: 15 days
Neurological deterioration and asymptomatic lesions on MRI due to DCI: asymptomatic MRI lesions
Time frame: 15 days
Neurological deterioration and asymptomatic lesions on MRI due to DCI: ischemic event
Time frame: 15 days
Total incidence of ischemic events per patient
Time frame: 15 days
Need for rescue therapy during embolization and/or DCI
Time frame: 14 days
Aneurysm occlusion
Time frame: 3 months
Clinical outcome at 3 months: good functionnal outcome (disability and functional dependence)
Time frame: 3 months
Clinical outcome at 3 months: good functional outcome (disability and recovery)
Time frame: 3 months
Clinical outcome at 3 months: quality of life
Time frame: 3 months
Clinical outcome at 3 months: cognitive deterioration
Time frame: 3 months
Clinical outcome at 3 months: deaths
Time frame: 3 months
Occurence of adverse events
Time frame: 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Subarachnoid Hemorrhage, Aneurysmal
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
RecruitingObservational study
Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Spontaneous, Subarachnoid Hemorrhage, Aneurysmal
Not yet recruitingPhase 1/2
Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)
Aneurysmal Subarachnoid Hemorrhage
RecruitingPhase 2
Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Aneurysmal, Headache
Not yet recruiting
Endovascular Therapy for Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Aneurysmal, Cerebral Vasospasm After Subarachnoid Hemorrhage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lionel Calvière principal investigator
Toulouse Hospital University
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Experimental group: ticagrelor in people with Subarachnoid Hemorrhage, Aneurysmal and Brain Ischemia, run by University Hospital, Toulouse at 7 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lionel Calvière, MD (05 61 77 94 86 ext. +33, calviere.l@chu-toulouse.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Effect of tricagrelor on the ischemic complications: peri-procedural thromboembolic events (time frame: 24 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.